Severe Acute Respiratory Syndrome (SARS) Treatments

Find Severe Acute Respiratory Syndrome (SARS) Treatments

Brand Name

Veklury

Generic Name

Remdesivir

View Brand Information

FDA approval date: November 01, 2020

Classification: SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

Form: Injection

What is Veklury (Remdesivir)?

VEKLURY is indicated for the treatment of coronavirus disease 2019 in adults and pediatric patients who are : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. VEKLURY is a severe acute respiratory syndrome coronavirus 2 nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 in adults and pediatric patients who are: Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

Approved To Treat

Severe Acute Respiratory Syndrome (SARS)

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, RANDOMIZED, DOUBLE-BLIND, 3-ARM STUDY TO INVESTIGATE IBUZATRELVIR IN ADULTS WITH SYMPTOMATIC COVID-19 WHO ARE SEVERELY IMMUNOCOMPROMISED

Enrollment Status: Recruiting

Publish Date: April 13, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the efficacy and safety of ibuzatrelvir alone and in combination with remdesivir IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who are non-hospitalized or are hospitalized for observation or study interventio...

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

Enrollment Status: Recruiting

Publish Date: April 06, 2026

Intervention Type: Drug

Summary: The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treati...

An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies

Enrollment Status: Recruiting

Publish Date: February 27, 2026

Intervention Type: Other, Procedure, Drug

Study Phase: Phase 2

Summary: This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one...

View All Clinical Trials

Related Latest Advances

Porcine hemagglutinating encephalomyelitis virus nucleocapsid protein targets RIG-I and IRF3 to evade IFN immunity.

Journal: Journal of virology

Published: March 30, 2026

FDA-approved drug library screen identifies antidepressants, antimicrobials, anti-COPD, and anti-CVD agents as blockers of NLRP3 inflammasome and sepsis in a sex-dependent manner.

Journal: bioRxiv : the preprint server for biology

Published: March 23, 2026

Electrocardiographic Profile of Adult Patients with Coronavirus Disease (COVID-19) who were Given Remdesivir and Admitted in the University of the Philippines-Philippine General Hospital (UP-PGH).

Journal: Acta medica Philippina

Published: March 16, 2026

View All Latest Advances

Brand Information

Veklury (remdesivir)

1INDICATIONS AND USAGE

VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are

Hospitalized, or
Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.

2DOSAGE FORMS AND STRENGTHS

VEKLURY for injection, 100 mg, available as a sterile, preservative-free white to off-white to yellow lyophilized powder in single-dose vial for reconstitution.

3CONTRAINDICATIONS

VEKLURY is contraindicated in patients with a history of clinically significant hypersensitivity reactions to VEKLURY or any components of the product

4ADVERSE REACTIONS

The following adverse reactions are discussed in other sections of the labeling:

Hypersensitivity Including Infusion-related and Anaphylactic Reactions
Increased Risk of Transaminase Elevations

4.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

5OVERDOSAGE

There is no human experience of acute overdosage with VEKLURY. Treatment of overdose with VEKLURY should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient. There is no specific antidote for overdose with VEKLURY.

6DESCRIPTION

VEKLURY contains remdesivir, a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor. The chemical name for remdesivir is 2-ethylbutyl

VEKLURY for injection contains 100 mg of remdesivir as a sterile, preservative-free lyophilized white to off-white to yellow powder in a single-dose clear glass vial. It requires reconstitution and then further dilution prior to administration by intravenous infusion

7PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

8PRINCIPAL DISPLAY PANEL - 100 mg Vial Label

Veklury

Single-Dose Vial: Discard

Must be reconstituted and

90288101

PRINCIPAL DISPLAY PANEL - 100 mg Vial Label

9PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton

NDC 61958-2901-2

Veklury

Single-Dose Vial: Discard

Must be reconstituted and

GILEAD

PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton